Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 11.02.2019 | 07:00

Continued profitable growth for Carl Zeiss Meditec in the first three months of 2018/19

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results

11.02.2019 / 07:00
The issuer is solely responsible for the content of this announcement.


Continued profitable growth for Carl Zeiss Meditec in the first three months of 2018/19
 
Successful start to new fiscal year, with both strategic business units contributing
 

JENA, February 11, 2019

In the first three months of fiscal year 2018/19 Carl Zeiss Meditec generated revenue of EUR323.6m, representing an increase of 9.8% (adjusted for currency effects: +9.0%) compared with the same period of the previous year (prior year: EUR294.7m). Significant growth was posted in the EMEA[1] region, particularly in its core markets Germany, France and Southern Europe. Earnings before interest and taxes (EBIT) increased significantly to EUR48.1m (prior year: EUR38.9m). The EBIT margin also increased, to 14.9% (prior year: 13.2%).

"We have made a successful start to the new financial year and were able to further expand our market share in both strategic business units," explains Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Solid growth in both strategic business units

The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 10.7 percent in the first three months of fiscal year 2018/19 (adjusted for currency effects: +9.8 percent), to EUR239.5m, compared with EUR216.3m in the same period of the prior year. This revenue increase was mainly attributable to laser vision correction systems as well as devices and consumables in cataract surgery.

Revenue in the Microsurgery SBU grew by 7.4 percent (adjusted for currency effects: +6.7 percent), to EUR84.2m, compared with EUR78.4m in the same period of the prior year. Sales of neurosurgical visualization systems for the treatment of tumors and vascular disease also remained buoyant.

Significant growth, particularly in the EMEA region

Revenue in the EMEA region increased by 13.5 percent (adjusted for currency effects: +15.1 percent), to EUR103.5m (prior year: EUR91.2m). Germany, France and Southern Europe posted strong revenue growth.

At EUR91.9m (prior year: EUR94.1; -2.3%, adjusted for currency effects: -4.9%), revenue in the first three months of the current fiscal year in the Americas region was slightly below the prior year's figure. This development is primarily attributable to new product launches at the beginning of the 2017/18 fiscal year, which had provided a strong boost to revenue in the same period of the prior year.

The APAC[2] region also posted a further increase in its revenue, of 17.1% (adjusted for currency effects: +16.2%) to EUR128.2m (prior year: EUR109.5m).

The operating result (earnings before interest and taxes: EBIT) increased significantly and reached EUR48.1m in the first three months of the current fiscal year (prior year: EUR38.9m). The EBIT margin increased from 13.2 percent to 14.9 percent. Adjusted for special effects, this represented an increase of 15.1% (prior year: 13.5 percent). Earnings of EUR0.32 per share remained at the same level as the previous year.

For fiscal 2018/19, we are expecting to grow at least as fast as our markets, which is confirmed by our business performance in the last three months. We are also holding to our margin target. We are expecting an EBIT margin in the range of 14 to 16 percent in the current fiscal year and in the medium term," said Dr. Monz, confirming the forecast published in December 2018.
 

Revenue by strategic business unit

All figures in EURm 3 months 2018/19 3 months 2017/18 Change from prior year Change from prior year (adjusted for currency effects)
Ophthalmic Devices 239.5 216.3 +10.7% +9.8%
Microsurgery 84.2 78.4 +7.4% +6.7%
Overall group 323.6 294.7 +9.8% +9.0%
 

 

Revenue by region

All figures in EURm 3 months 2018/19 3 months 2017/18 Change from prior year Change from prior year (adjusted for currency effects)
EMEA 103.5 91.2 +13.5% +15.1%
Americas 91.9 94.1 -2.3% -4.9%
APAC 128.2 109.5 +17.1% +16.2%
Overall group 323.6 294.7 +9.8% +9.0%
 

 

Contact for investors and press
Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.de/presse

[1] Europe, Middle East, Africa
[2] Asia/Pacific



11.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

EQS Group: Rating lautet Kaufen

Die Vorzeichen für die EQS Group AG sind positiv. Ein wesentlicher Umsatztreiber für das Jahr 2020 sollte die Migration von Bestandskunden vom COCKPIT in das COCKPIT 2.0 bedeuten. Darüber hinaus erwarten wir ein gutes Wachstum in den übrigen Bereichen, da die EQS mit vielen Produkten auch von der Coronakrise profitieren kann. So werden z. B. Online-Hauptversammlungen, Webcasts und Telefonkonferenzen vermehrt gebucht: Unseres Erachtens sollte es auch zu einer höhere Anzahl an Pflichtmeldungen von Unternehmen kommen. Unser Kursziel liegt bei 91,50 €, das Rating lautet weiter Kaufen.

News im Fokus

Wirecard AG: Veröffentlichung des Konzernabschlusses am 18. Juni 2020; Konzernabschlussprüfung 2019 bislang ohne wesentliche Feststellungen; Unternehmen erwartet ein uneingeschränktes Testat

25. Mai 2020, 22:13

Aktuelle Research-Studie

Netfonds AG

Original-Research: Netfonds AG (von Montega AG): Kaufen

25. Mai 2020